Spatial omics strategies for investigating human carotid atherosclerotic disease

Abstract

Atherosclerosis is a chronic inflammatory condition of the arteries, marked by the development of plaques within the arterial intima. The rupture of unstable plaques can lead to thrombosis, downstream vessel occlusion and serious clinical events. The composition of atherosclerotic plaques is complex and highly heterogeneous, posing challenges for their study. The current pathology and histological subtype classification of plaques may fail to fully encompass the microscopic molecular components in the tissue, the disease progress in various stages of atherosclerosis and the potential mechanism of plaque rupture. However, spatial mapping of the heterogeneity in plaque tissue components can enhance our understanding of these lesions. Despite the considerable progress made by traditional omics in the field of disease research, and its status as an indispensable technology, there remain inherent limitations in the investigation of minute molecular. In recent years, spatial omics techniques have advanced significantly, enabling the visualisation and analysis of specific components within plaques that may serve as causal targets associated with disease progression. The effective application of spatial omics in both research and clinical settings represents a promising area for further exploration. This review focuses on the recent advancements and findings related to spatial omics in the study of extracranial carotid atherosclerotic cerebrovascular disease. Spatial omics analysis of atherosclerotic plaques can facilitate the detection of biomarkers with diagnostic significance or potential relevance to disease, offering new methods and insights into the diagnosis of atherosclerosis and its complications.

Keywords

atherosclerosis / biomarker / spatial distribution / spatial omics / vascular bed

References

[1] Feigin VL, Brainin M, Norrving B, et al. World Stroke Organization (WSO): global stroke fact sheet 2022. International Journal of Stroke. 2022; 17(1): 18-29.

[2] Eckstein HH, Kühnl A, Berkefeld J, et al. Diagnosis, treatment and follow-up in extracranial carotid stenosis. Deutsches Arzteblatt international. 2020; 117(47): 801-807.

[3] Christenson RH, Saenger AK. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem. 2010; 56(1): 21-33.

[4] Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update. Circulation. 2015; 131(4).

[5] Petty GW, Brown RD, Whisnant JP, et al. Ischemic stroke subtypes. Stroke. 1999; 30(12): 2513-2516.

[6] Naylor AR, Ricco JB, de Borst GJ, al et. Editor's choice—management of atherosclerotic carotid and vertebral artery disease: 2017 clinical practice guidelines of the european society for vascular surgery (ESVS). European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery. 2018; 55(1): 3-81.

[7] Puig N, Solé A, Aguilera-Simon A, et al. Novel therapeutic approaches to prevent atherothrombotic ischemic stroke in patients with carotid atherosclerosis. Int J Mol Sci. 2023(18): 24.

[8] Libby P. The changing landscape of atherosclerosis. Nature. 2021; 592(7855): 524-533.

[9] Bentzon JF, Otsuka F, Virmani R, et al. Mechanisms of plaque formation and rupture. Circ Res. 2014; 114(12): 1852-1866.

[10] Zhao M, Liu A, Mo L, et al. Higher expression of PLEK and LY86 as the potential biomarker of carotid atherosclerosis. Medicine (Baltimore). 2023(42): 102.

[11] Narula N, Olin JW, Narula N. Pathologic disparities between peripheral artery disease and coronary artery disease. Arterioscler Thromb Vasc Biol. 2020; 40(9): 1982-1989.

[12] Wu X, Zhang H. Omics approaches unveiling the biology of human atherosclerotic plaques. Am J Pathol. 2024.

[13] Bressan D, Battistoni G, Hannon GJ. The dawn of spatial omics. Science. 2023; 381(6657): eabq4964.

[14] Park J, Kim J, Lewy T, et al. Spatial omics technologies at multimodal and single cell/subcellular level. Genome Biol. 2022; 23(1): 256.

[15] Hu M, Wang S. Chromatin tracing: imaging 3D genome and nucleome. Trends Cell Biol. 2021; 31(1): 5-8.

[16] Bhatia HS, Brunner AD, Öztürk F, et al. Spatial proteomics in three-dimensional intact specimens. Cell. 2022; 185(26): 5040-5058.

[17] Kuett L, Catena R, Özcan A, et al. Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment. Nat Cancer. 2022; 3(1): 122-133.

[18] Xie YR, Castro DC, Rubakhin SS, et al. Multiscale biochemical mapping of the brain through deep-learning-enhanced high-throughput mass spectrometry. Nat Methods. 2024; 21(3): 521-530.

[19] Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016; 17(6): 333-351.

[20] Ren P, Zhang R, Wang Y, et al. Systematic benchmarking of high-throughput subcellular spatial transcriptomics platforms. Biorxiv. 2024: 2024.12.23.630033.

[21] Rao A, Barkley D, França GS, et al. Exploring tissue architecture using spatial transcriptomics. Nature. 2021; 596(7871): 211-220.

[22] Rodriques SG, Stickels RR, Goeva A, et al. Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019; 363(6434): 1463-1467.

[23] Liu Y, Yang M, Deng Y, et al. High-spatial-resolution multi-omics sequencing via deterministic barcoding in tissue. Cell. 2020; 183(6): 1665-1681. e18.

[24] Wu L, Yan J, Bai Y, et al. An invasive zone in human liver cancer identified by stereo-seq promotes hepatocyte-tumor cell crosstalk, local immunosuppression and tumor progression. Cell Res. 2023; 33(8): 585-603.

[25] Kishi JY, Liu N, West ER, et al. Light-Seq: light-directed in situ barcoding of biomolecules in fixed cells and tissues for spatially indexed sequencing. Nat Methods. 2022; 19(11): 1393-1402.

[26] Moses L, Pachter L. Museum of spatial transcriptomics. Nat Methods. 2022; 19(5): 534-546.

[27] Gyllborg D, Langseth CM, Qian X, et al. Hybridization-based in situ sequencing (HybISS) for spatially resolved transcriptomics in human and mouse brain tissue. Nucleic Acids Res. 2020; 48(19): e112.

[28] Lee JH, Daugharthy ER, Scheiman J, et al. Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues. Nat Protoc. 2015; 10(3): 442-458.

[29] Alon S, Goodwin DR, Sinha A, et al. Expansion sequencing: spatially precise in situ transcriptomics in intact biological systems. Science. 2021; 371(6528).

[30] Lubeck E, Coskun AF, Zhiyentayev T, et al. Single-cell in situ RNA profiling by sequential hybridization. Nat Methods. 2014; 11(4): 360-361.

[31] Eng CL, Lawson M, Zhu Q, et al. Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH. Nature. 2019; 568(7751): 235-239.

[32] Chen KH, Boettiger AN, Moffitt JR, et al. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science. 2015; 348(6233): aaa6090.

[33] Shah S, Takei Y, Zhou W, et al. Dynamics and spatial genomics of the nascent transcriptome by intron seqFISH. Cell. 2018; 174(2): 363-376. e16.

[34] Lundberg E, Borner GHH. Spatial proteomics: a powerful discovery tool for cell biology. Nat Rev Mol Cell Biol. 2019; 20(5): 285-302.

[35] Skogs M, Stadler C, Schutten R, et al. Antibody validation in bioimaging applications based on endogenous expression of tagged proteins. J Proteome Res. 2017; 16(1): 147-155.

[36] Gut G, Herrmann MD, Pelkmans L. Multiplexed protein maps link subcellular organization to cellular states. Science. 2018(6401): 361.

[37] Radtke AJ, Kandov E, Lowekamp B, et al. IBEX: a versatile multiplex optical imaging approach for deep phenotyping and spatial analysis of cells in complex tissues. Proc Nat Acad Sci USA. 2020; 117(52): 33455-33465.

[38] Arakkal L. IBEX: a user-friendly and open-source solution for high-plex immunostaining. Nat Rev Immunol. 2023; 23(12): 783.

[39] Goltsev Y, Samusik N, Kennedy-Darling J, et al. Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. Cell. 2018; 174(4): 968-981. e15.

[40] Black S, Phillips D, Hickey JW, et al. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat Protoc. 2021; 16(8): 3802-3835.

[41] Saka SK, Wang Y, Kishi JY, et al. Immuno-SABER enables highly multiplexed and amplified protein imaging in tissues. Nat Biotechnol. 2019; 37(9): 1080-1090.

[42] Hosogane T, Casanova R, Bodenmiller B. DNA-barcoded signal amplification for imaging mass cytometry enables sensitive and highly multiplexed tissue imaging. Nat Methods. 2023; 20(9): 1304-1309.

[43] Groseclose MR, Andersson M, Hardesty WM, et al. Identification of proteins directly from tissue: in situ tryptic digestions coupled with imaging mass spectrometry. J Mass Spectrometr. 2007; 42(2): 254-262.

[44] He C, Migawa MT, Chen K, et al. High-resolution visualization and quantification of nucleic acid-based therapeutics in cells and tissues using nanoscale secondary ion mass spectrometry (NanoSIMS). Nucleic Acids Res. 2021; 49(1): 1-14.

[45] Spraggins JM, Djambazova KV, Rivera ES, et al. High-performance molecular imaging with MALDI trapped ion-mobility time-of-flight (timsTOF) mass spectrometry. Anal Chem. 2019; 91(22): 14552-14560.

[46] Fiorentino G, Smith A, Nicora G, et al. MALDI mass spectrometry imaging shows a gradual change in the proteome landscape during mouse ovarian folliculogenesis. Mol Hum Reprod. 2023; 29(4).

[47] Claes BSR, Krestensen KK, Yagnik G, et al. MALDI-IHC-guided in-depth spatial proteomics: targeted and untargeted MSI combined. Anal Chem. 2023; 95(4): 2329-2338.

[48] Jiang X, Li T, Zhou Y, et al. A new direction in metabolomics: analysis of the central nervous system based on spatially resolved metabolomics. TrAC, Trends Anal Chem. 2023; 165: 117103.

[49] Zhang H, Lu KH, Ebbini M, et al. Mass spectrometry imaging for spatially resolved multi-omics molecular mapping. Npj Imaging. 2024; 2(1): 20.

[50] Verbeeck N, Caprioli RM, Van de Plas R. Unsupervised machine learning for exploratory data analysis in imaging mass spectrometry. Mass Spectrom Rev. 2020; 39(3): 245-291.

[51] Zhao C, Dong J, Deng L, et al. Molecular network strategy in multi-omics and mass spectrometry imaging. Curr Opin Chem Biol. 2022; 70: 102199.

[52] Moore JL, Charkoftaki G. A guide to MALDI imaging mass spectrometry for tissues. J Proteome Res. 2023; 22(11): 3401-3417.

[53] Ellis SR, Brown SH, In Het Panhuis M, et al. Surface analysis of lipids by mass spectrometry: more than just imaging. Prog Lipid Res. 2013; 52(4): 329-353.

[54] Harris GA, Galhena AS, Fernández FM. Ambient sampling/ionization mass spectrometry: applications and current trends. Anal Chem. 2011; 83(12): 4508-4538.

[55] Lee ES, Shon HK, Lee TG, et al. The regional ratio of cholesteryl palmitate to cholesteryl oleate measured by ToF-SIMS as a key parameter of atherosclerosis. Atherosclerosis. 2013; 226(2): 378-384.

[56] Passarelli MK, Winograd N. Lipid imaging with time-of-flight secondary ion mass spectrometry (ToF-SIMS). Biochim Biophys Acta. 2011; 1811(11): 976-990.

[57] Kandanaarachchi S, Gardner W, Alexander DLJ, et al. Comparison of tiling artifact removal methods in secondary ion mass spectrometry images. Anal Chem. 2023; 95(47): 17384-17391.

[58] Greco F, Quercioli L, Pucci A, et al. Mass spectrometry imaging as a tool to investigate region specific lipid alterations in symptomatic human carotid atherosclerotic plaques. Metabolites. 2021; 11(4).

[59] Engel KM, Prabutzki P, Leopold J, et al. A new update of MALDI-TOF mass spectrometry in lipid research. Prog Lipid Res. 2022; 86: 101145.

[60] Mezger STP, Mingels AMA, Bekers O, et al. Trends in mass spectrometry imaging for cardiovascular diseases. Anal BioanalChem. 2019; 411(17): 3709-3720.

[61] Berry KA, Hankin JA, Barkley RM, et al. MALDI imaging of lipid biochemistry in tissues by mass spectrometry. Chem Rev. 2011; 111(10): 6491-6512.

[62] Chen LC, Lee C, Hsu CC. Towards developing a matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) compatible tissue expansion protocol. Anal Chim Acta. 2024; 1297: 342345.

[63] Kompauer M, Heiles S, Spengler B. Atmospheric pressure MALDI mass spectrometry imaging of tissues and cells at 1.4-µm lateral resolution. Nat Methods. 2017; 14(1): 90-96.

[64] Takáts Z, Wiseman JM, Gologan B, et al. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. Science. 2004; 306(5695): 471-473.

[65] Manicke NE, Nefliu M, Wu C, et al. Imaging of lipids in atheroma by desorption electrospray ionization mass spectrometry. Anal Chem. 2009; 81(21): 8702-8707.

[66] Morato NM, Cooks RG. Desorption electrospray ionization mass spectrometry: 20 years. Acc Chem Res. 2023; 56(18): 2526-2536.

[67] He J, Sun C, Li T, al et. A sensitive and wide coverage ambient mass spectrometry imaging method for functional metabolites based molecular histology. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2018; 5(11): 1800250.

[68] Wu C, Dill AL, Eberlin LS, et al. Mass spectrometry imaging under ambient conditions. Mass Spectrom Rev. 2013; 32(3): 218-243.

[69] Tian L, Chen F, Macosko EZ. The expanding vistas of spatial transcriptomics. Nat Biotechnol. 2023; 41(6): 773-782.

[70] Ståhl PL, Salmén F, Vickovic S, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016; 353(6294): 78-82.

[71] Kawai K, Sakamoto A, Mokry M, et al. Clonal proliferation within smooth muscle cells in unstable human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2023; 43(12): 2333-2347.

[72] Murry CE, Gipaya CT, Bartosek T, et al. Monoclonality of smooth muscle cells in human atherosclerosis. Am J Pathol. 1997; 151(3): 697-705.

[73] Sun J, Singh P, Shami A, et al. Spatial transcriptional mapping reveals site-specific pathways underlying human atherosclerotic plaque rupture. J Am Coll Cardiol. 2023; 81(23): 2213-2227.

[74] Ravindran A, Holappa L, Niskanen H, et al. Translatome profiling reveals Itih4 as a novel smooth muscle cell-specific gene in atherosclerosis. Cardiovasc Res. 2024.

[75] Zhang L, Liang X, Takáč T, et al. Spatial proteomics of vesicular trafficking: coupling mass spectrometry and imaging approaches in membrane biology. Plant Biotechnol J. 2023; 21(2): 250-269.

[76] Tan C, Liu Y, Li W, et al. Associations of matrix metalloproteinase-9 and monocyte chemoattractant protein-1 concentrations with carotid atherosclerosis, based on measurements of plaque and intima-media thickness. Atherosclerosis. 2014; 232(1): 199-203.

[77] Bhosale SD, Moulder R, Venäläinen MS, et al. Serum proteomic profiling to identify biomarkers of premature carotid atherosclerosis. Sci Rep. 2018; 8(1): 9209.

[78] Baragetti A, Mattavelli E, Grigore L, et al. Targeted plasma proteomics to predict the development of carotid plaques. Stroke. 2022; 53(9): e411-e414.

[79] Bao Q, Zhang B, Zhou L, et al. CNP ameliorates macrophage inflammatory response and atherosclerosis. Circ Res. 2024.

[80] Aherrahrou R, Baig F, Theofilatos K, et al. Secreted protein profiling of human aortic smooth muscle cells identifies vascular disease associations. Arterioscler Thromb Vasc Biol. 2024.

[81] Chen W, Tumanov S, Stanley CP, et al. Destabilization of atherosclerotic plaque by bilirubin deficiency. Circ Res. 2023; 132(7): 812-827.

[82] Rashid I, Maghzal GJ, Chen YC, et al. Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque. Eur Heart J. 2018; 39(35): 3301-3310.

[83] Lai Z, Wang C, Liu X, et al. Characterization of the proteome of stable and unstable carotid atherosclerotic plaques using data-independent acquisition mass spectrometry. J Transl Med. 2024; 22(1): 247.

[84] Schneider MK, Wang J, Kare A, et al. Combined near infrared photoacoustic imaging and ultrasound detects vulnerable atherosclerotic plaque. Biomaterials. 2023; 302: 122314.

[85] Alseekh S, Fernie AR. Metabolomics 20 years on: what have we learned and what hurdles remain?. Plant Journal: for cell and molecular biology. 2018; 94(6): 933-942.

[86] Lehti S, Sjövall P, Käkelä R, al et. Spatial distributions of lipids in atherosclerosis of human coronary arteries studied by time-of-flight secondary ion mass spectrometry. Am J Pathol. 2015; 185(5): 1216-1233.

[87] Li HW, Hu Z, Chen X, et al. Investigation of lipid metabolism in dynamic progression of coronary artery atherosclerosis of humans by time-of-flight secondary ion mass spectrometry. Anal Chem. 2021; 93(8): 3839-3847.

[88] Zaima N, Sasaki T, Tanaka H, et al. Imaging mass spectrometry-based histopathologic examination of atherosclerotic lesions. Atherosclerosis. 2011; 217(2): 427-432.

[89] Martin-Lorenzo M, Balluff B, Maroto AS, al et. Lipid and protein maps defining arterial layers in atherosclerotic aorta. Data in brief. 2015; 4: 328-331.

[90] Patterson NH, Doonan RJ, Daskalopoulou SS, et al. Three-dimensional imaging MS of lipids in atherosclerotic plaques: open-source methods for reconstruction and analysis. Proteomics. 2016; 16(11-12): 1642-1651.

[91] Visscher M, Moerman AM, Burgers PC, et al. Data processing pipeline for lipid profiling of carotid atherosclerotic plaque with mass spectrometry imaging. J Am Soc Mass Spectrom. 2019; 30(9): 1790-1800.

[92] Moerman AM, Visscher M, Slijkhuis N, et al. Lipid signature of advanced human carotid atherosclerosis assessed by mass spectrometry imaging. J Lipid Res. 2021; 62: 100020.

[93] Li W, Luo J, Peng F, et al. Spatial metabolomics identifies lipid profiles of human carotid atherosclerosis. Atherosclerosis. 2023; 364: 20-28.

[94] Slijkhuis N, Towers M, Mirzaian M, et al. Identifying lipid traces of atherogenic mechanisms in human carotid plaque. Atherosclerosis. 2023; 385: 117340.

[95] Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007; 26(1): 51-78.

[96] Cao J, Martin-Lorenzo M, van Kuijk K, et al. Spatial metabolomics identifies LPC(18:0) and LPA(18:1) in advanced atheroma with translation to plasma for cardiovascular risk estimation. Arterioscler Thromb Vasc Biol. 2024; 44(3): 741-754.

[97] Shaikh S, Brittenden J, Lahiri R, et al. Macrophage subtypes in symptomatic carotid artery and femoral artery plaques. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery. 2012; 44(5): 491-497.

[98] Sulkava M, Raitoharju E, Levula M, et al. Differentially expressed genes and canonical pathway expression in human atherosclerotic plaques—Tampere vascular study. Sci Rep. 2017; 7: 41483.

[99] Levula M, Oksala N, Airla N, et al. Genes involved in systemic and arterial bed dependent atherosclerosis-Tampere vascular study. PLoS One. 2012; 7(4): e33787.

[100] Martin-Lorenzo M, Balluff B, Maroto AS, et al. Molecular anatomy of ascending aorta in atherosclerosis by MS imaging: specific lipid and protein patterns reflect pathology. J Proteomics. 2015; 126: 245-251.

[101] Cao J, Goossens P, Martin-Lorenzo M, et al. Atheroma-specific lipids in ldlr(-/-) and apoe(-/-) mice using 2D and 3D matrix-assisted laser desorption/ionization mass spectrometry imaging. J Am Soc Mass Spectrom. 2020; 31(9): 1825-1832.

[102] Shen L, Yamamoto T, Tan XW, et al. Identification and visualization of oxidized lipids in atherosclerotic plaques by microscopic imaging mass spectrometry-based metabolomics. Atherosclerosis. 2020; 311: 1-12.

[103] Khamehgir-Silz P, Gerbig S, Volk N, et al. Comparative lipid profiling of murine and human atherosclerotic plaques using high-resolution MALDI MSI. Pflugers Archiv: European journal of physiology. 2022; 474(2): 231-242.

[104] Seeley EH, Liu Z, Yuan S, et al. Spatially resolved metabolites in stable and unstable human atherosclerotic plaques identified by mass spectrometry imaging. Arterioscler Thromb Vasc Biol. 2023; 43(9): 1626-1635.

[105] Slijkhuis N, Razzi F, Korteland SA, et al. Spatial lipidomics of coronary atherosclerotic plaque development in a familial hypercholesterolemia swine model. J Lipid Res. 2024; 65(2): 100504.

[106] Steenman M, Espitia O, Maurel B, et al. Identification of genomic differences among peripheral arterial beds in atherosclerotic and healthy arteries. Sci Rep. 2018; 8(1): 3940.

[107] Wu X, Pan X, Zhou Y, et al. Identification of key genes for atherosclerosis in different arterial beds. Sci Rep. 2024; 14(1): 6543.

[108] Sukhanov S, Higashi Y, Yoshida T, et al. Insulin-like growth factor 1 reduces coronary atherosclerosis in pigs with familial hypercholesterolemia. JCI Insight. 2023; 8(4).

[109] Elishaev M, Hodonsky CJ, Ghosh SKB, et al. Opportunities and challenges in understanding atherosclerosis by human biospecimen studies. Front Cardiovasc Med. 2022; 9: 948492.

[110] Vandereyken K, Sifrim A, Thienpont B, et al. Methods and applications for single-cell and spatial multi-omics. Nat Rev Genet. 2023; 24(8): 494-515.

[111] Kiessling P, Kuppe C. Spatial multi-omics: novel tools to study the complexity of cardiovascular diseases. Genome medicine. 2024; 16(1): 14.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.